Response to “Letter to the Editor Regarding a Multicenter Phase 2 Randomized Controlled Study on the Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients with COVID-19 Pneumonia”

Detalles Bibliográficos
Autor principal: Mantelli, Flavio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9684829/
https://www.ncbi.nlm.nih.gov/pubmed/36417164
http://dx.doi.org/10.1007/s40121-022-00727-4
_version_ 1784835375230877696
author Mantelli, Flavio
author_facet Mantelli, Flavio
author_sort Mantelli, Flavio
collection PubMed
description
format Online
Article
Text
id pubmed-9684829
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-96848292022-11-28 Response to “Letter to the Editor Regarding a Multicenter Phase 2 Randomized Controlled Study on the Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients with COVID-19 Pneumonia” Mantelli, Flavio Infect Dis Ther Letter Springer Healthcare 2022-11-22 2023-01 /pmc/articles/PMC9684829/ /pubmed/36417164 http://dx.doi.org/10.1007/s40121-022-00727-4 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Letter
Mantelli, Flavio
Response to “Letter to the Editor Regarding a Multicenter Phase 2 Randomized Controlled Study on the Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients with COVID-19 Pneumonia”
title Response to “Letter to the Editor Regarding a Multicenter Phase 2 Randomized Controlled Study on the Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients with COVID-19 Pneumonia”
title_full Response to “Letter to the Editor Regarding a Multicenter Phase 2 Randomized Controlled Study on the Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients with COVID-19 Pneumonia”
title_fullStr Response to “Letter to the Editor Regarding a Multicenter Phase 2 Randomized Controlled Study on the Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients with COVID-19 Pneumonia”
title_full_unstemmed Response to “Letter to the Editor Regarding a Multicenter Phase 2 Randomized Controlled Study on the Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients with COVID-19 Pneumonia”
title_short Response to “Letter to the Editor Regarding a Multicenter Phase 2 Randomized Controlled Study on the Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients with COVID-19 Pneumonia”
title_sort response to “letter to the editor regarding a multicenter phase 2 randomized controlled study on the efficacy and safety of reparixin in the treatment of hospitalized patients with covid-19 pneumonia”
topic Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9684829/
https://www.ncbi.nlm.nih.gov/pubmed/36417164
http://dx.doi.org/10.1007/s40121-022-00727-4
work_keys_str_mv AT mantelliflavio responsetolettertotheeditorregardingamulticenterphase2randomizedcontrolledstudyontheefficacyandsafetyofreparixininthetreatmentofhospitalizedpatientswithcovid19pneumonia

Ejemplares similares